A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease; Dementia; Lewy body disease; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 08 Jan 2018 Results presented in an Axovant Sciences media release.
    • 08 Jan 2018 According to a company media release, Axovant Sciences has decided to discontinue intepirdine program based on negative results from MINDSET, HEADWAY and Gait and Balance studies.
    • 08 Jan 2018 Primary endpoint (Change in quantitative gait measurements from baseline to the end of each double-blind treatment period based on computerized gait assessment tools) has not been met, according to an Axovant Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top